Oct 2026· European journal of medicinal chemistry· Vol 321 Pt 2, pp.
119414
· 0 citations· 50 references
Medicine
TL;DR
A new non-CITCO chemotype for hCAR activation is established and YA8026 is identified as a promising lead compound for further development following the discovery of a structurally distinct class of hCAR activators based on the 2,4-diaminopyrimidine scaffold of ML241.
Abstract
The human constitutive androstane receptor (hCAR) regulates drug metabolism and represents a promising target for enhancing cyclophosphamide (CPA) bioactivation through CYP2B6 induction. However, currently available hCAR activators are mostly derived from the CITCO scaffold and often exhibit suboptimal physicochemical properties. Here, we report the discovery of a structurally distinct class of hCAR activators based on the 2,4-diaminopyrimidine scaffold of ML241, a known p97 ATPase inhibitor identified through high-throughput screening (HTS). Systematic structure-activity relationship (SAR) studies enabled optimization of this scaffold and led to the identification of 43 (YA8026) as a potent and selective hCAR activator. YA8026 demonstrated sub-micromolar potency, favorable selectivity over human pregnane X receptor (hPXR) and other nuclear receptors, and robust functional activity in human primary hepatocytes, including selective CYP2B6 induction and hCAR nuclear translocation. Notably, these compounds no longer retained p97 inhibitory activity, highlighting successful scaffold repurposing. In addition, YA8026 exhibited minimal kinase inhibition across a panel of 280 kinases, favorable chemical and plasma stability, and low cellular toxicity. Together, this work establishes a new non-CITCO chemotype for hCAR activation and identifies YA8026 as a promising lead compound for further development.
The discovery of a pyrazolopyrimidine series as potent and orally bioavailable MRGPRX2 antagonists and establish the pyrazolopyrimidine chemotype as a promising scaffold for inhibition of MRGPRX2 signaling are established.
Minh-Hai Nguyen, Hai-Fen Ye, Heeoon Han et al.· ACS Medicinal Chemistry Lett...· 0 citations
ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-specific guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of three scaff...
A. Tarhan, Zhi-Ping Feng, Daniel Fernández et al.· Journal of Medicinal Chemist...· 0 citations
Mechanistic studies shown that compound E6 increased global m6A levels in AML cells, upregulated the FTO downstream targets ASB2 and RARA, and suppressed c-Myc expression, and provided novel chemical scaffold for discovery of FTO inhibitor against leukemia.
Yu-Meng Wang, Ya-Ting Lu, Hao-Dong Liu et al.· Journal of Medicinal Chemist...· 0 citations
Castration-resistant prostate cancer relies on intratumoral androgen synthesis mediated by cytochrome P450 17A1 (CYP17A1). Treatment with the only clinically used CYP17A1 inhibitor, abiraterone, is limited by resistance and side effects, underscoring the urgent need for new CYP17A1 inhibitors with greater selectivity a...
Angelika Grudzińska, J. Yakubu, C. Vigato et al.· ChemMedChem· 0 citations
PKMYT1 mediates the inhibitory phosphorylation of CDK1 and represents a promising synthetic lethal target in p53-deficient or CCNE1-amplified malignancies. A series of PKMYT1 inhibitors featuring a novel monocyclic pyridine core structure was discovered, exhibiting improved selectivity and enhanced drug-like properties...
Cytochrome P450 1B1 (CYP1B1) is a drug-metabolizing enzyme that is overexpressed in a variety of malignant tumors. Therefore, CYP1B1 has emerged as an important therapeutic target for cancer treatment and the management of drug resistance. In this study, we employed the pharmacophore fusion strategy to optimize the str...